Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ongentys
Synonyms :
opicapone
Class :
Antiparkinson Agents, COMT Inhibitors
Brand Name :
Ongentys
Synonyms :
opicapone
Class :
Antiparkinson Agents, COMT Inhibitors
Dosage forms & Strengths:
Tablet
25 mg
50 mg
Safety and efficacy are not seen in pediatrics
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with MAO inhibitors
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may enhance the serum concentration
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may decrease the therapeutic effect of antiparkinson agents
may decrease the anti-psychotic therapeutic effect
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect of Antipsychotic Agents
may enhance the serum concentration of ubrogepant
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may increase the levels of serum concentration of elagolix
may enhance the serum concentration of elbasvir/grazoprevir
metoclopramide decreases the efficacy of antiparkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of antiparkinson agents
it decreases the efficacy of antiparkinson agents
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
may increase the serum concentration of OAT1/3 substrates
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the serum concentration of COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
It may enhance the serum concentration when combined with COMT Substrates
may decrease the therapeutic effect of each other when combined
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
>10%:
Dyskinesia
1-10%:
Increased blood creatine kinase
Hypotension/syncope
Decreased weight
Dry mouth
Dizziness
Hallucinations
Opicapone is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
No data is available regarding the usage during pregnancy.
Breastfeeding warnings:
No data is available regarding the usage during lactation.
Pregnancy category:
Patient information leaflet
Generic Name: opicapone
Pronounced: oh-pik-a-pone
Why do we use opicapone?
Opicapone belongs to the category of antiparkinson agent. It helps treat Parkinson’s disease.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
